At the news
? NEUTRALIMPACT 3/10 S-3 filed Nov 9, 2026 at 18:39 ET
ADC Therapeutics filed an S-3 registration statement to register 61,000,000 common shares for resale by investors who participated in the October 2026 $86.6M PIPE. The company will not receive proceeds from share sales but may receive up to CHF 3.8M if pre-funded warrants are exercised for cash. This filing is a routine contractual obligation from the PIPE, not a new offering, and follows the company's recent debt restructuring and Q3 revenue growth.
- S-3 registers 61,000,000 common shares for resale by selling shareholders from the October 2026 PIPE
- Includes 12,911,347 common shares and 48,088,653 shares issuable upon exercise of pre-funded warrants
- Company will not receive proceeds from share sales; may receive up to CHF 3,847,092 if pre-funded warrants exercised for cash
- PIPE raised $86.6M at $1.42 per share and $1.324 per pre-funded warrant, closed October 22, 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access